Zacks Research Lowers Earnings Estimates for Cosmos Health

Cosmos Health Inc. (NASDAQ:COSM) – Research analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for shares of Cosmos Health in a research report issued on Thursday, May 21st. Zacks Research analyst B. Sorensen now forecasts that the company will earn $0.01 per share for the year, down from their prior forecast of $0.08. The consensus estimate for Cosmos Health’s current full-year earnings is $0.08 per share. Zacks Research also issued estimates for Cosmos Health’s Q4 2026 earnings at $0.04 EPS.

Cosmos Health (NASDAQ:COSM) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.The company had revenue of $18.40 million for the quarter, compared to analyst estimates of $17.93 million.

Cosmos Health Trading Up 4.0%

Shares of Cosmos Health stock opened at $0.26 on Wednesday. Cosmos Health has a fifty-two week low of $0.25 and a fifty-two week high of $1.32. The firm has a market cap of $14.29 million, a PE ratio of -0.41 and a beta of 5.00. The business’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.44. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in COSM. Citadel Advisors LLC lifted its stake in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares during the period. Renaissance Technologies LLC raised its position in shares of Cosmos Health by 260.5% in the 4th quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after buying an additional 241,775 shares during the period. Finally, XTX Topco Ltd raised its position in shares of Cosmos Health by 52.1% in the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after buying an additional 34,117 shares during the period. Hedge funds and other institutional investors own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.